Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis
Точность тестов на онкобелки HPV E6/E7 для выявления цервикальных поражений высокой степени: систематический обзор литературы и метаанализ
2023-11-16
SCID: 54.1/vxbqqepf
Discuss with AI
HPV E6/E7 oncoprotein testscervical intraepithelial neoplasia grade 3diagnostic accuracyhigh-risk HPV-positive womensystematic review and meta-analysis
Figures from the paper
Abstract (AI)
BACKGROUND: Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-positive women. METHODS: We conducted a systematic review and meta-analysis assessing the accuracy of HPV-E6/E7-oncoprotein tests to detect underlying cervical-precancer and cancer. We included studies reporting data on oncoprotein test accuracy detecting cervical intraepithelial neoplasia grade 3 or worse. Random effects logistic regression models were applied for pooling absolute and relative accuracy. RESULTS: Twenty-two studies were included. Sensitivity and specificity estimates ranged from 54.2% (95%CI: 45.2-63.0) to 69.5% (95%CI:60.8-76.9) and from 82.8% (95%CI: 50.4-95.8) to 99.1 (95%CI: 98.8-99.3), respectively in the population irrespective of HPV status. Higher sensitivity estimates ranging from 60.8% (95%CI: 49.6-70.9) to 75.5% (95%CI: 71.7-78.9) but lower specificity estimates ranging from 83.7% (95%CI: 76.1-89.3) to 92.1% (95%CI: 88.5-94.6) were observed in studies enrolling high-risk-HPV-positive women. Studies recruiting only HIV-positive women showed a pooled sensitivity of 46.9% (95%CI: 30.6-63.9) with a specificity of 98.0% (95%CI: 96.8-98.7). CONCLUSIONS: The high specificity of oncoprotein tests supports its use for triaging HPV-positive women. However, oncoprotein-negative women would not be recommended to undertake routine screening, requiring further follow-up. Large-scale and longitudinal studies are needed to further investigate the role of E6/E7-oncoprotein detection in predicting the risk of developing cervical pre-cancer and cancer.
Key Findings
1
A systematic review and meta-analysis included 22 studies evaluating HPV E6/E7 oncoprotein tests for detecting cervical intraepithelial neoplasia grade 3 or worse.
2
Among HIV-positive women, pooled sensitivity was 46.9% and specificity was 98.0%.
3
Among women regardless of HPV status, pooled sensitivity estimates ranged from 54.2% to 69.5%, while specificity ranged from 82.8% to 99.1%.
4
High specificity supports using E6/E7 oncoprotein tests to triage HPV-positive women, but negative results require continued follow-up rather than routine screening alone.
5
In high-risk-HPV-positive women, sensitivity was higher at 60.8–75.5%, but specificity was lower at 83.7–92.1%.
6
Large-scale longitudinal studies are needed to determine whether E6/E7-oncoprotein detection predicts future cervical precancer and cancer risk.
Research Object
HPV E6/E7 oncoprotein tests for detecting cervical intraepithelial neoplasia grade 3 or worse, cervical precancer, and cancer
Research Subject
Diagnostic accuracy, including sensitivity and specificity, of HPV E6/E7 oncoprotein tests for detecting high-grade cervical lesions across different HPV and HIV-status populations
Publication Details
Publication Date
2023-11-16
Journal
Publisher
ISSN
Cited by
28
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest